Anti-toxin provider Jiangxi Institute joins biopharma IPO rush
The company enjoys a big share of China’s anti-tetanus market but is looking to diversify into antidotes for rabies and snake bites to drive future growth Key Takeaways: The company…
WuXi group wrestles with uncertainty over pharma tariffs
Drugs services giant WuXi AppTec cashed in a stake in Wuxi XDC to soften the blow from a first round of Trump tariffs, as the pharma sector braces for another…
Investors cheer Akeso’s revenue milestone, even as it returns to the red
The drugmaker’s shares rallied after the release of its strong annual report, up by a cumulative 18% over the next three trading days Key Takeaways: Akeso’s drug sales rose 25%…
BRIEF: Hutchmed profit falls on shrinking R&D income
Hutchmed (China) Ltd. (HCM.US; 0013.HK; HCM.L), a biopharmaceutical company controlled by CK Hutchison Holdings (0001.HK), said its revenue fell 24.8% last year to $630 million, according to its annual results…
BRIEF: Ascentage Pharma prices U.S. IPO at 20% discount, to raise up to $130 million
Biopharmaceutical company Ascentage Pharma Group International (6855.HK) announced Friday that it will offer 7.325 million American Depositary Shares (ADS) in its upcoming U.S. listing at an issue price of $17.25…
BRIEF: Ascentage Pharma gets Chinese regulatory nod for U.S. listing
Biopharmaceutical company Ascentage Pharma Group International (6855.HK) received a listing approval notice from the China Securities Regulatory Commission (CSRC) on Monday, a necessary step before it can make an overseas…
PODCAST: A Biotech Buyout, and an Influencer Uprising
By Doug Young & Rene Vanguestaine AstraZeneca has offered to buy money-losing Gracell Biotech for up to $1.2 billion, in a first-of-its kind M&A for a Chinese drug startup. Will…